- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00641290
Vigileo FloTrac vs Pulmonary Artery Catheter
Cardiac Output and Central Venous Oxygen Saturation Monitoring Using the Vigileo FloTrac Sensor Versus Conventional Thermodilution Method Using the Pulmonary Artery Catheter: A Prospective Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Cardiac Output and Central Venous Oxygen Saturation Monitoring Using the Vigileo FloTrac Sensor Versus Conventional Thermodilution Method Using the Pulmonary Artery Catheter: A Prospective Study
OBJECTIVE: To study the role of Vigileo monitor using the FloTrac sensor to measure cardiac output using the pulse contour analysis as well as central venous oxygen saturation monitoring as a guide for tissue perfusion. The accuracy of the Vigileo monitoring was compared with the conventional thermodilution method for measuring cardiac output using the pulmonary artery catheter and mixed venous oxygen saturation for assessing global tissue perfusion.
DESIGN: A prospective clinical study conducted at the cardiothoracic operating theatre and the cardiothoracic intensive care unit of Sultanah Aminah Hospital Johor Bahru.
PARTICIPANTS: 60 patients from the time of induction of anaesthesia to post operative Day 1 in the cardiothoracic intensive care unit.
INTERVENTIONS: Simultaneous cardiac output measurements using the Vigileo FloTrac sensor and thermodilution method using the PAC will be obtained at the following intervals: Post Induction( T0), Pre CPB( T1), Post CPB( T2), 1 hour post ICU admission( T3), 4 hours post ICU admission( T4), 1 hour post extubation( T5) and post operative Day 1 at 0700(T6). Central venous oxygen saturation measurements and mixed venous oxygen saturation using the PAC was also obtained at similar interval times as above. Low central venous oxygen saturation is defined as less than 70% while low mixed venous oxygen saturation was fixed as less than 65% for appropriate interventions to be instituted to improve oxygen delivery. Arterial blood gases will also be done at the scheduled interval to validate whether the presence of metabolic acidosis can be used to correlate with central or mixed venous oxygen saturation measurements.
MEASUREMENTS AND RESULTS: Demographic data that was recorded include age, sex, body weight, height, and body mass index, type of surgery, ejection fraction, time on cardiopulmonary bypass, Euroscore, haemoglobin and haematocrit levels.
At the scheduled interval, cardiac output measurements using the thermodilution method as well as the pulse contour analysis method using the Vigileo FloTrac system will be done. Mixed venous oxygen (SvO2) will be sampled simultaneously with the central venous oxygen saturation (ScvO2 ).
Demographic data will be summarized as mean ± SD where appropriate. Bland -Altman plot will be done to compare both methods for obtaining the cardiac output measurements. Linear regression analysis, Bland-Altman plot and Pearson test will be used to evaluate the correlation between SvO2 and ScvO2. A p-value of < 0.05 will be considered as significant.
EXCLUSION CRITERIA: Patients will be excluded if they are on Intra Aortic Balloon Pump (IABP), requiring emergency chest reopening, significant arrhythmia which causes an irregular arterial waveform and tricuspid regurgitation as ruled out during the pre operative echocardiogram.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Gunalan P Arumugam, MBBS
- Phone Number: 0060122057474
- Email: gunalan73@yahoo.com
Study Locations
-
-
Johor
-
Johor Bahru, Johor, Malaysia, 80100
- Hospital Sultanah Aminah
-
Principal Investigator:
- Gunalan P Arumugam, MBBS
-
Sub-Investigator:
- Raha M. Daud, MD
-
Sub-Investigator:
- Zanariah Sabiron, MD
-
Sub-Investigator:
- Salamah Azerai, MD
-
Sub-Investigator:
- Subrahmanyam Balan, MBBS
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- All patients who are undergoing coronary bypass graft surgery and valvular heart disease.
Exclusion Criteria:
- Patients will be excluded if they are on Intra Aortic Balloon Pump (IABP), requiring emergency chest reopening, significant arrhythmia which causes an irregular arterial waveform and tricuspid regurgitation as ruled out during the pre operative echocardiogram.
Study Plan
How is the study designed?
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Cardiac output and other haemodynamic indices
Time Frame: 48 hours
|
48 hours
|
Collaborators and Investigators
Investigators
- Study Chair: Subrahmanyam Balan, MBBS, Hospital Sultanah Aminah Johor Bahru
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NMRR ID 08-645-1800
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ischemic Heart Disease
-
Genzyme, a Sanofi CompanyTerminatedIschemic Heart Disease | Ischemic Cardiomyopathy | Ischemic Heart FailureBelgium, France, Germany, Italy, Switzerland, United Kingdom
-
Cardiocentro TicinoTerminatedChronic Ischemic Heart DiseaseSwitzerland
-
University of AlbertaRecruitingCoronary Artery Disease | Stable Ischemic Heart Disease | Beta-blocker TherapyCanada
-
Gerencia de Atención Primaria, MadridServicio Canario de Salud; Avedis Donabedian Research InstituteCompletedIschemic Heart Disease ChronicSpain
-
Michael SekelaCompletedChronic Ischemic Heart DiseaseUnited States
-
University of PecsCompleted
-
Rigshospitalet, DenmarkNot yet recruitingChronic Ischemic Heart DiseaseDenmark
-
The University of Texas Health Science Center,...National Heart, Lung, and Blood Institute (NHLBI); Cardiovascular Cell Therapy...CompletedIschemic Cardiomyopathy | Left Ventricular Dysfunction | Angina | Chronic Ischemic Heart DiseaseUnited States
-
Affiliated Hospital to Academy of Military Medical...Ivy Institute of Stem Cells Co. LtdUnknownHeart Failure | Angina | Chronic Ischemic Heart DiseaseChina
-
University of EdinburghUnknown
Clinical Trials on Vigileo FloTrac Sensor
-
M.D. Anderson Cancer CenterEdwards LifesciencesCompletedLiver Diseases | Gastrointestinal Diseases | Kidney Diseases | Esophageal Diseases | Prostate Cancer | Pancreatic Diseases | Gynecologic Diseases | Spinal Disease | Disorder of the Genitourinary SystemUnited States
-
Chinese PLA General HospitalCompletedArtificial; Complications, HeartChina
-
University Tunis El ManarCompletedHemodynamic InstabilityTunisia
-
Hôpital Européen MarseilleTerminatedCritically Ill | Acute Circulatory Failure | Fluid LoadingFrance
-
University Hospital Inselspital, BerneEdwards LifesciencesCompletedVasodilation | Vasoconstriction | Hemodynamics | Cardiac Output, Low | Cardiac Output, HighSwitzerland
-
Regina Elena Cancer InstituteCompletedPostoperative ComplicationsItaly
-
Juan Victor LorenteEdwards LifesciencesCompleted
-
Beijing Tongren HospitalCompletedGoal-directed Fluid TherapyChina
-
Université Libre de BruxellesCompleted
-
Seoul National University HospitalRecruitingLiver Diseases | Liver Cirrhosis | Liver Transplant; Complications | End Stage Liver DIseaseKorea, Republic of